Unveiling the masked native blood group following thalidomide therapy in a thalassemia patient: A 5 WHY analysis approach

Policy for prevention and control of hemoglobinopathies – Thalassemia, Sickle cell disease and Variant hemoglobin in India 2018. Ministry of Health and Family Welfare, Government of India, New Delhi. Available at https://www.nhp.gov.in/NHPfiles/1.pdf. Last accessed on 01/12/2021. Colah, 2017, Burden of thalassemia in India: the road map for control, Pediatr Hematol Oncol, 2, 79, 10.1016/j.phoj.2017.10.002 Lippi, 2011, Identification errors in the blood transfusion laboratory: a still relevant issue for patient safety, Transfus Apher Sci, 44, 231, 10.1016/j.transci.2011.01.021 Meny, 2017, Recognizing and resolving ABO discrepancies, Immunohematology, 33, 76, 10.21307/immunohematology-2019-012 Li, 2021, Efficacy of thalidomide treatment in children with transfusion dependent β-thalassemia: a retrospective clinical study, Front Pharmacol, 12 Cappellini MD, Farmakis D., Porter J., Taher A. 2021 Guidelines for the management of transfusion dependent thalassemia (TDT). 4th ed. Thalassemia International Federation; 2021. Available at 〈https://www.thalassemia.org/boduw/wp-content/uploads/2021/06/TIF-2021-Guidelines-for-Mgmt-of-TDT.pdf〉. Last accessed on 01/12/2021. Unni, 2014, Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions, Transfusion, 54, 98, 10.1111/trf.12251 Avent N.D., Reid M.E. The Rh blood group system: a review. Blood. 2000 Jan 15;95(2):375–387. Erratum in: Blood 2000 Apr 1;95(7):2197. PMID: 10627438. Hendrickson, 2016, Understanding Red Blood Cell Alloimmunization Triggers, 2016, 446 Yang, 2020, Thalidomide for patients with β-thalassemia: a multicenter experience, Mediterr J Hematol Infect Dis., 12, 10.4084/mjhid.2020.021